Premature ovarian insufficiency and autoimmune profiles: a prospective case–control study

References

• Luisi S, Orlandini C, Regini C, et al. Premature ovarian insufficiency: from pathogenesis to clinical management. J Endocrinol Invest. 2015;38(6):597–603. doi: 10.1007/s40618-014-0231-1.
   PubMed Web of Science ®Google Scholar
• Podfigurna-Stopa A, Czyzyk A, Grymowicz M, et al. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Invest. 2016;39(9):983–990. doi: 10.1007/s40618-016-0467-z.
   PubMed Web of Science ®Google Scholar
• Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.
   PubMed Web of Science ®Google Scholar
• Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2019;60:42–55. doi: 10.1016/j.bpobgyn.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Chen J, Wu S, Wang M, et al. A review of autoimmunity and immune profiles in patients with primary ovarian insufficiency. Medicine. 2022;101(51):e32500. doi: 10.1097/MD.0000000000032500.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–1599. doi: 10.1016/j.fertnstert.2016.09.046.
   PubMed Web of Science ®Google Scholar
• Ebrahimi M, Asbagh A. F. The role of autoimmunity in premature ovarian failure. Iran J Reprod Med. 2015;13(8):461–472.
   PubMedGoogle Scholar
• Sharif K, Watad A, Bridgewood C, et al. Insights into the autoimmune aspect of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101323. doi: 10.1016/j.beem.2019.101323.
   PubMed Web of Science ®Google Scholar
• Vujovic S, Brincat M, Erel T, et al. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010;67(1):91–93. doi: 10.1016/j.maturitas.2010.04.011.
   PubMed Web of Science ®Google Scholar
• Lebovic DI, Naz R. Premature ovarian failure: think ‘autoimmune Disorder’. Sexuality, Reproduction and Menopause. 2004;2(4):230–233. doi: 10.1016/j.sram.2004.11.010.
   Google Scholar
• Alper MM, Garner PR. Premature ovarian failure: its relationship to autoimmune disease. Obstet Gynecol. 1985;66(1):27–30.
   PubMed Web of Science ®Google Scholar
• Conway GS, Kaltsas G, Patel A, et al. Characterization of idiopathic premature ovarian failure. Fertil Steril. 1996;65(2):337–341. doi: 10.1016/s0015-0282(16)58095-9.
   PubMed Web of Science ®Google Scholar
• Collins G, Patel B, Thakore S, et al. Primary Ovarian insufficiency: current concepts. South Med J. 2017;110(3):147–153. doi: 10.14423/SMJ.0000000000000611.
   PubMed Web of Science ®Google Scholar
• Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int J Mol Sci. 2021;22(5):2594.
   Web of Science ®Google Scholar
• Kim TJ, Anasti JN, Flack MR, et al. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol. 1997;89(5 Pt 1):777–779. doi: 10.1016/s0029-7844(97)00077-x.
   PubMed Web of Science ®Google Scholar
• Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36(11):2207–2215. doi: 10.1007/s10815-019-01572-0.
   PubMed Web of Science ®Google Scholar
• Beitl K, Rosta K, Poetsch N, et al. Autoimmunological serum parameters and bone mass density in premature ovarian insufficiency: a retrospective cohort study. Arch Gynecol Obstet. 2021;303(4):1109–1115. doi: 10.1007/s00404-020-05860-4.
   PubMed Web of Science ®Google Scholar
• Ciaccio C, Fontana L, Milani D, et al. Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr. 2017;43(1):39. doi: 10.1186/s13052-017-0355-y.
   PubMedGoogle Scholar
• Bagni C, Tassone F, Neri G, et al. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12):4314–4322. doi: 10.1172/JCI63141.
   PubMed Web of Science ®Google Scholar
• Hager M, Ott J, Marschalek J, et al. Basal and dynamic relationships between serum anti-Müllerian hormone and gonadotropins in patients with functional hypothalamic amenorrhea, with or without polycystic ovarian morphology. Reprod Biol Endocrinol. 2022;20(1):98. doi: 10.1186/s12958-022-00961-y.
   PubMed Web of Science ®Google Scholar
• Beitl K, Dewailly D, Seemann R, et al. Polycystic ovary syndrome phenotype D versus functional hypothalamic amenorrhea with polycystic ovarian morphology: a retrospective study about a frequent differential diagnosis. Front Endocrinol. 2022;13:904706. doi: 10.3389/fendo.2022.904706.
   PubMed Web of Science ®Google Scholar
• Hager M, Dewailly D, Marculescu R, et al. Stress and polycystic ovarian morphology in functional hypothalamic amenorrhea: a retrospective cohort study. Reprod Biol Endocrinol. 2023;21(1):42. doi: 10.1186/s12958-023-01095-5.
   PubMed Web of Science ®Google Scholar
• Levit E, Singh B, Nylander E, et al. A systematic review of autoimmune oophoritis therapies. Reprod Sci. 2023. doi: 10.1007/s43032-023-01299-5.
   PubMed Web of Science ®Google Scholar
• Prall SP, Muehlenbein MP. DHEA modulates immune function: a review of evidence. Vitam Horm. 2018;108:125–144. doi: 10.1016/bs.vh.2018.01.023.
   PubMed Web of Science ®Google Scholar
• Doldi N, Belvisi L, Bassan M, et al. Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol Endocrinol. 1998;12(1):23–28. doi: 10.3109/09513599809024966.
   PubMed Web of Science ®Google Scholar
• Crosbie D, Black C, McIntyre L, et al. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev. 2007;(4):CD005114.
   Google Scholar
• Ott J, Pecnik P, Promberger R, et al. Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto’s thyroiditis. Climacteric. 2014;17(1):92–96. doi: 10.3109/13697137.2013.800040.
   PubMed Web of Science ®Google Scholar
• Yeung TWY, Li RHW, Lee VCY, et al. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab. 2013;98(1):380–388. doi: 10.1210/jc.2012-3071.
   PubMed Web of Science ®Google Scholar
• Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: evidence from a meta-analysis. J Gynecol Obstet Hum Reprod. 2017;46(1):1–7. doi: 10.1016/j.jgyn.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Goswami R, Marwaha RK, Goswami D, et al. Prevalence of thyroid autoimmunity in sporadic idiopathic hypoparathyroidism in comparison to type 1 diabetes and premature ovarian failure. J Clin Endocrinol Metab. 2006;91(11):4256–4259. doi: 10.1210/jc.2006-1005.
   PubMed Web of Science ®Google Scholar
• Košir Pogačnik R, Meden Vrtovec H, Vizjak A, et al. Possible role of autoimmunity in patients with premature ovarian insufficiency. Int J Fertil Steril. 2014;7(4):281–290.
   PubMedGoogle Scholar
• Zhen X, Qiao J, Li R, et al. Serologic autoimmunologic parameters in women with primary ovarian insufficiency. BMC Immunol. 2014;15(1):11. doi: 10.1186/1471-2172-15-11.
   PubMedGoogle Scholar
• Pires ES, Parikh FR. The status of anti-ovarian antibody immunoassays: valid or invalid, in or out? Am J Reprod Immunol. 2023;89(2):e13617.
   PubMed Web of Science ®Google Scholar